Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.


Franco Rongioletti, MD
Section Editor
Jeffrey Callen, MD, FACP, FAAD
Deputy Editor
Abena O Ofori, MD


Scleromyxedema, also known as generalized and sclerodermoid lichen myxedematosus or Arndt-Gottron disease, is a primary cutaneous mucinosis characterized by a generalized papular and sclerodermoid cutaneous eruption that usually occurs in association with monoclonal gammopathy. Affected patients develop numerous waxy firm papules and plaques that demonstrate mucin deposition, increased fibroblast proliferation, and fibrosis on histologic examination. Systemic manifestations may involve the cardiovascular, gastrointestinal, pulmonary, musculoskeletal, renal, or nervous systems, and may lead to significant morbidity and mortality.

Scleromyxedema should be distinguished from localized lichen myxedematosus, a form of lichen myxedematosus that presents with waxy, firm papules and plaques involving limited areas. Unlike scleromyxedema, sclerotic features, systemic involvement, and monoclonal gammopathy are absent in localized lichen myxedematosus. Scleroderma and scleredema are additional disorders that present with sclerodermoid features but are unrelated to scleromyxedema. Scleromyxedema also is distinct from myxedema of thyroid disease. (See "Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults" and "Scleredema" and "Clinical manifestations of hypothyroidism", section on 'Skin'.)

The clinical features, diagnosis, and management of scleromyxedema will be reviewed here.


Scleromyxedema is a rare disease that usually affects middle-aged adults between the ages of 30 and 80 years with no race or sex predominance [1]. In a multicenter retrospective study of 30 patients with scleromyxedema, the mean age of affected patients was 59 years [1]. This illness has not been reported in infants and young children.


The pathogenesis of scleromyxedema is unknown. The significance of the associated monoclonal gammopathy and the underlying plasma cell clone is debated. The main hypothesis is that circulating cytokines such as interleukin (IL)-1, TNF-alpha, and TGF-beta, known to stimulate glycosaminoglycan synthesis and fibroblast proliferation in the skin, could play a role [2-4]. Clinical remission of scleromyxedema following autologous stem cell transplantation suggests that the bone marrow may be a source of these circulating factors [2,5].

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Oct 2017. | This topic last updated: Apr 04, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Rongioletti F, Merlo G, Cinotti E, et al. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol 2013; 69:66.
  2. Rongioletti F, Rebora A. Mucinoses. In: Dermatology, 3rd ed, Bolognia J, Jorizzo JL, Schaffer JV, et al (Eds), Elsevier, Philadelphia 2012. Vol 1, p.687.
  3. Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg 2006; 25:100.
  4. Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006; 24:493.
  5. Feasel AM, Donato ML, Duvic M. Complete remission of scleromyxedema following autologous stem cell transplantation. Arch Dermatol 2001; 137:1071.
  6. Harper RA, Rispler J. Lichen myxedematosus serum stimulates human skin fibroblast proliferation. Science 1978; 199:545.
  7. Ferrarini M, Helfrich DJ, Walker ER, et al. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989; 16:837.
  8. Yaron M, Yaron I, Yust I, Brenner S. Lichen myxedematosus (scleromyxedema) serum stimulates hyaluronic acid and prostaglandin E production by human fibroblasts. J Rheumatol 1985; 12:171.
  9. Yeung CK, Loong F, Kwong YL. Scleromyxoedema due to a plasma cell neoplasm: rapid remission with bortezomib, thalidomide and dexamethasone. Br J Haematol 2012; 157:411.
  10. Migkou M, Gkotzamanidou M, Terpos E, et al. Response to bortezomib of a patient with scleromyxedema refractory to other therapies. Leuk Res 2011; 35:e209.
  11. Rongioletti F, Cattarini G, Sottofattori E, Rebora A. Granulomatous reaction after intradermal injections of hyaluronic acid gel. Arch Dermatol 2003; 139:815.
  12. Rongioletti F, Hazini A, Rebora A. Coma associated with scleromyxoedema and interferon alfa therapy. Full recovery after steroids and cyclophosphamide combined with plasmapheresis. Br J Dermatol 2001; 144:1283.
  13. Fleming KE, Virmani D, Sutton E, et al. Scleromyxedema and the dermato-neuro syndrome: case report and review of the literature. J Cutan Pathol 2012; 39:508.
  14. Berger JR, Dobbs MR, Terhune MH, Maragos WF. The neurologic complications of scleromyxedema. Medicine (Baltimore) 2001; 80:313.
  15. Rey JB, Luria RB. Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin. J Am Acad Dermatol 2009; 60:1037.
  16. Espinosa A, De Miguel E, Morales C, et al. Scleromyxedema associated with arthritis and myopathy: a case report. Clin Exp Rheumatol 1993; 11:545.
  17. Jamieson TW, De Smet AA, Stechschulte DJ. Erosive arthropathy associated with scleromyxedema. Skeletal Radiol 1985; 14:286.
  18. Helfrich DJ, Walker ER, Martinez AJ, Medsger TA Jr. Scleromyxedema myopathy: case report and review of the literature. Arthritis Rheum 1988; 31:1437.
  19. Launay D, Hatron PY, Delaporte E, et al. Scleromyxedema (lichen myxedematosus) associated with dermatomyositis. Br J Dermatol 2001; 144:359.
  20. Rothe MJ, Rivas R, Gould E, Kerdel FA. Scleromyxedema and severe myositis. Int J Dermatol 1989; 28:657.
  21. Ozdag F, Akar A, Eroglu E, Erbil H. Acute rhabdomyolysis during the treatment of scleromyxedema with interferon alfa. J Dermatolog Treat 2001; 12:167.
  22. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol 2003; 42:31.
  23. De Simone C, Castriota M, Carbone A, et al. Cardiomyopathy in scleromyxedema: report of a fatal case. Eur J Dermatol 2010; 20:852.
  24. Morris-Jones R, Staughton RC, Walker M, et al. Lichen myxoedematosus with associated cardiac abnormalities. Br J Dermatol 2001; 144:594.
  25. Dinneen AM, Dicken CH. Scleromyxedema. J Am Acad Dermatol 1995; 33:37.
  26. Blum M, Wigley FM, Hummers LK. Scleromyxedema: a case series highlighting long-term outcomes of treatment with intravenous immunoglobulin (IVIG). Medicine (Baltimore) 2008; 87:10.
  27. Le Moigne M, Mazereeuw-Hautier J, Bonnetblanc JM, et al. [Clinical characteristics, outcome of scleromyxoedema: a retrospective multicentre study]. Ann Dermatol Venereol 2010; 137:782.
  28. Rapp MF, Guram M, Konrad HR, et al. Laryngeal involvement in scleromyxedema: a case report. Otolaryngol Head Neck Surg 1991; 104:362.
  29. Lee YH, Sahu J, O'Brien MS, et al. Scleroderma renal crisis-like acute renal failure associated with mucopolysaccharide accumulation in renal vessels in a patient with scleromyxedema. J Clin Rheumatol 2011; 17:318.
  30. Godby A, Bergstresser PR, Chaker B, Pandya AG. Fatal scleromyxedema: report of a case and review of the literature. J Am Acad Dermatol 1998; 38:289.
  31. Loggini B, Pingitore R, Avvenente A, et al. Lichen myxedematosus with systemic involvement: clinical and autopsy findings. J Am Acad Dermatol 2001; 45:606.
  32. Gonzalez J, Palangio M, Schwartz J, et al. Scleromyxedema with dermato-neuro syndrome. J Am Acad Dermatol 2000; 42:927.
  33. Chan JC, Trendell-Smith NJ, Yeung CK. Scleromyxedema: a cutaneous paraneoplastic syndrome associated with thymic carcinoma. J Clin Oncol 2012; 30:e27.
  34. Alfadley A, Al Hoqail I, Al Eisa A. Scleromyxedema: possible association with seminoma. J Am Acad Dermatol 2000; 42:875.
  35. Giménez Garcia R, Garcia SG, Suarez Vilela D, Moro Sanchez MJ. Scleromyxedema associated with non-Hodgkin lymphoma. Int J Dermatol 1989; 28:670.
  36. Hardie RA, Hunter JA, Urbaniak S, Habeshaw JA. Spontaneous resolution of lichen myxoedematosus. Br J Dermatol 1979; 100:727.
  37. Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol 2001; 23:257.
  38. Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273.
  39. Stücker M, Nowack U, Röchling A, et al. Sweat gland proliferations in scleromyxedema. Am J Dermatopathol 1999; 21:259.
  40. Rongioletti F, Cozzani E, Parodi A. Scleromyxedema with an interstitial granulomatous-like pattern: a rare histologic variant mimicking granuloma annulare. J Cutan Pathol 2010; 37:1084.
  41. Rongioletti F, Merlo G, Carli C, et al. Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases. J Am Acad Dermatol 2016; 74:1194.
  42. Delyon J, Bézier M, Rybojad M, et al. Specific lymph node involvement in scleromyxedema: a new diagnostic entity for hypermetabolic lymphadenopathy. Virchows Arch 2013; 462:679.
  43. Clements PI, Meedsger TA Jr, Feghali CA. Cutaneous involvement in systemic sclerosis. In: Systemic sclerosis, 2nd ed, Clements PI, Furst DE. (Eds), Lippincott Williams and Wilkins, 2004.
  44. Farmer ER, Hambrick GW Jr, Shulman LE. Papular mucinosis. A clinicopathologic study of four patients. Arch Dermatol 1982; 118:9.
  45. Krajnc I, Vizjak A, Hvala A, et al. [Significance of histopathologic analysis of skin lesions in scleromyxedema. Light microscopy, electron microscopy, immunohistochemistry and immunofluorescence microscopy]. Acta Med Austriaca 1998; 25:109.
  46. Serra S, Ambrósio C, João Salvador M, et al. [A cutaneous thickening case...]. Acta Reumatol Port 2010; 35:66.
  47. Nashel J, Steen V. Scleroderma mimics. Curr Rheumatol Rep 2012; 14:39.
  48. Weedon D. Cutaneous mucinoses. In: Weedon's Skin Pathology, 3rd ed., Elsevier Limited, 2010. p.353.
  49. Bidier M, Zschoche C, Gholam P, et al. Scleromyxoedema: clinical follow-up after successful treatment with high-dose immunoglobulins reveals different long-term outcomes. Acta Derm Venereol 2012; 92:408.
  50. Bos R, de Waal EG, Kuiper H, et al. Thalidomide and dexamethasone followed by autologous stem cell transplantation for scleromyxoedema. Rheumatology (Oxford) 2011; 50:1925.
  51. Sroa N, Campbell S, Bechtel M. Intravenous immunoglobulin therapy for scleromyxedema: a case report and review of literature. J Drugs Dermatol 2010; 9:263.
  52. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291:484.
  53. Molina V, Blank M, Shoenfeld Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol 2005; 29:321.
  54. Gholam P, Hartmann M, Enk A. Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins. Br J Dermatol 2007; 157:1058.
  55. Körber A, Franckson T, Grabbe S, Dissemond J. Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin. J Eur Acad Dermatol Venereol 2007; 21:553.
  56. Righi A, Schiavon F, Jablonska S, et al. Intravenous immunoglobulins control scleromyxoedema. Ann Rheum Dis 2002; 61:59.
  57. Binitha MP, Nandakumar G, Thomas D. Suspected cardiac toxicity to intravenous immunoglobulin used for treatment of scleromyxedema. Indian J Dermatol Venereol Leprol 2008; 74:248.
  58. Efthimiou P, Blanco M. Intravenous gammaglobulin and thalidomide may be an effective therapeutic combination in refractory scleromyxedema: case report and discussion of the literature. Semin Arthritis Rheum 2008; 38:188.
  59. Sansbury JC, Cocuroccia B, Jorizzo JL, et al. Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients. J Am Acad Dermatol 2004; 51:126.
  60. Guarenti I, Sebastiani V, Pinto G, et al. Successful treatment of scleromyxedema with oral thalidomide. Int J Dermatol 2013; 52:631.
  61. Amini-Adle M, Thieulent N, Dalle S, et al. Scleromyxedema: successful treatment with thalidomide in two patients. Dermatology 2007; 214:58.
  62. Jacob SE, Fien S, Kerdel FA. Scleromyxedema, a positive effect with thalidomide. Dermatology 2006; 213:150.
  63. Martins A, Paiva Lopes MJ, Tavares Belo R, Rodrigues JC. Scleromyxedema--thalidomide therapy. J Eur Acad Dermatol Venereol 2008; 22:622.
  64. Thyssen JP, Zachariae C, Menné T. Successful treatment of scleromyxedema using thalidomide. J Eur Acad Dermatol Venereol 2006; 20:1396.
  65. Brunet-Possenti F, Hermine O, Marinho E, et al. Combination of intravenous immunoglobulins and lenalidomide in the treatment of scleromyxedema. J Am Acad Dermatol 2013; 69:319.
  66. Wright RC, Franco RS, Denton D, Blaney DJ. Scleromyxedema. Arch Dermatol 1976; 112:63.
  67. Rayson D, Lust JA, Duncan A, Su WP. Scleromyxedema: a complete response to prednisone. Mayo Clin Proc 1999; 74:481.
  68. Lin YC, Wang HC, Shen JL. Scleromyxedema: An experience using treatment with systemic corticosteroid and review of the published work. J Dermatol 2006; 33:207.
  69. Kreuter A, Altmeyer P. High-dose dexamethasone in scleromyxedema: report of 2 additional cases. J Am Acad Dermatol 2005; 53:739.
  70. Horn KB, Horn MA, Swan J, et al. A complete and durable clinical response to high-dose dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol 2004; 51:S120.
  71. Cañueto J, Labrador J, Román C, et al. The combination of bortezomib and dexamethasone is an efficient therapy for relapsed/refractory scleromyxedema: a rare disease with new clinical insights. Eur J Haematol 2012; 88:450.
  72. Bonnetblanc JM, Bedane C. Regression of scleromyxedema with topical betamethasone and dimethyl sulfoxide: a 30-month follow-up. Arch Dermatol 1991; 127:1733.
  73. Reynolds NJ, Collins CM, Burton JL. Discrete papular mucinosis responding to intralesional and topical steroids. Arch Dermatol 1992; 128:857.
  74. Hisler BM, Savoy LB, Hashimoto K. Improvement of scleromyxedema associated with isotretinoin therapy. J Am Acad Dermatol 1991; 24:854.
  75. Milam CP, Cohen LE, Fenske NA, Ling NS. Scleromyxedema: therapeutic response to isotretinoin in three patients. J Am Acad Dermatol 1988; 19:469.
  76. Tschen JA, Chang JR. Scleromyxedema: treatment with interferon alfa. J Am Acad Dermatol 1999; 40:303.
  77. Saigoh S, Tashiro A, Fujita S, et al. Successful treatment of intractable scleromyxedema with cyclosporin A. Dermatology 2003; 207:410.
  78. Kuldeep CM, Mittal AK, Gupta LK, et al. Successful treatment of scleromyxedema with dexamethasone cyclophosphamide pulse therapy. Indian J Dermatol Venereol Leprol 2005; 71:44.
  79. Mehta V, Balachandran C, Rao R. Arndt Gottron scleromyxedema: successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol 2009; 54:193.
  80. Schirren CG, Betke M, Eckert F, Przybilla B. [Arndt-Gottron scleromyxedema. Case report and review of therapeutic possibilities]. Hautarzt 1992; 43:152.
  81. Davis LS, Sanal S, Sangueza OP. Treatment of scleromyxedema with 2-chlorodeoxyadenosine. J Am Acad Dermatol 1996; 35:288.
  82. Rongioletti F, Rebora A. Worsening of lichen myxedematosus during interferon alfa-2a therapy for chronic active hepatitis C. J Am Acad Dermatol 1998; 38:760.
  83. Brenner M, Herzinger T, Berking C, et al. Phototherapy and photochemotherapy of sclerosing skin diseases. Photodermatol Photoimmunol Photomed 2005; 21:157.
  84. Kantor GR, Bergfeld WF, Katzin WE, et al. Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol 1986; 14:879.
  85. Rampino M, Garibaldi E, Ragona R, Ricardi U. Scleromyxedema: treatment of widespread cutaneous involvement by total skin electron-beam therapy. Int J Dermatol 2007; 46:864.
  86. Yamazaki S, Fujisawa T, Yanatori A, Yamakage A. A case of lichen myxedematosus with clearly exacerbated skin eruptions after UVB irradiation. J Dermatol 1995; 22:590.
  87. Shayegi N, Alakel N, Middeke JM, et al. Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema. Transl Res 2015; 165:321.
  88. River Y, Levy I, Gilead L, et al. Fever, convulsions and coma in scleromyxedema: a "dermato-neuro syndrome". Neurology 1996; 46:1778.
  89. Fett NM, Toporcer MB, Dalmau J, et al. Scleromyxedema and dermato–neuro syndrome in a patient with multiple myeloma effectively treated with dexamethasone and bortezomib. Am J Hematol 2011; 86:893.
  90. Acikel C, Karagoz H, Kucukodaci Z. Surgical treatment of facial disfigurement due to lichen myxedematosus. Dermatol Surg 2009; 35:875.
  91. Kaymen AH, Nasr A, Grekin RC. The use of carbon dioxide laser in lichen myxedematosus. J Dermatol Surg Oncol 1989; 15:862.